Calyxo secured a $40 million Series F financing as its CVAC system surpassed 40,000 patients treated for kidney stone removal.
- Amount
- $40M
- Stage
- Series F
- Announced
- 14 April 2026
- Leads
- Ally Bridge Group, Janus Henderson Investors
- Other investors
- Questa Capital, Avidity Partners, CRG
- Use of funds
- Expand commercial infrastructure, advance clinical and health economic evidence generation, and support continued innovation in kidney stone care.
- Checked
- Amount and date checked against the press source